Slide 1: Q3 FY23 Business Update Presentation
Q3 FY23 Business Update Presentation Melbourne, Australia, April 19, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated d
Slide 2: About Travelan®
About Travelan® Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized
Slide 3: Investor Presentation Business Update April, 2023
INVESTOR PRESENTATION BUSINESS UPDATE 19 APRIL, 2023 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC 1
Slide 4: Safe Harbor Statement
SAFE HARBOR STATEMENT Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressio
Slide 5: Executive Summary
EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases • Two commercially available oral immunotherapeutic products – Travelan® and Protect
Slide 6: Sales | Year To Date | 14th April 2023
SALES | YEAR TO DATE | 14TH APRIL 2023 A$000s Key Commentary FY23 YTD FY22YTD Profit & Loss Var % • Strong start to Q4 2023 (to 14 April 2023) 14 April 2023 14 April 2022 Australian Sales $ 1,184 $ 137 764% • $320k Net Sales; up 233% YTD on pcp Rest of World Sales $ 595 $ 397 50% • Supply chain capa
Slide 7: Key Milestones Anticipated To Drive Value
KEY MILESTONES ANTICIPATED TO DRIVE VALUE 2H 1H 2H 1H 2022 2023 2023 2024 • FDA IND1 approved for • IRB Approval4 • Topline results for IMM- • Clinical Study Report Travelan® single daily dose IMM-124E • Initiate IMM-124E ETEC 124E ETEC CHIM clinical ETEC2 CHIM3 clinical trial a CHIM clinical trial
Slide 8: Steven Lydeamore Chief Executive Officer Immuron Limited
Steven Lydeamore Chief Executive Officer Immuron Limited 19 April 2023 Contact Information: Phone: Australia: +613 8892 4854 Email: steve@immuron.com 6
Slide 9: Technology Platform
TECHNOLOGY PLATFORM Immuron’s proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can be used to target virus
Slide 10: Addressable Market & Industry Overview
ADDRESSABLE MARKET & INDUSTRY OVERVIEW Billion Dollar Market Travelers diarrhea treatment market is large and growing at a Immuron’s products are a subset of the global digestive health ~$15b+ market, which a multi-billion-dollar market* CAGR of ~7% Travelers diarrhea treatment market is large and g
Slide 11: Immuron’s Clinical Programs – Opportunity Assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT Lumanity* Opportunity Assessment for IMM-124E b Lumanity Opportunity Assessment for IMM-529 c • Immuron’s development of IMM-124E (hyperimmune bovine • Infectious disease experts reacted favorably to the IMM-529 MOA, and colostrum) as a prescripti
Slide 12: Scientific References
SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% of Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: volunteers 10.3109/00365521.2011.574726 Travelan as a broad Spectrum anti-bacterial I
Slide 13: ASX Releases Referenced
ASX RELEASES REFERENCED Ref Slide statement ASX Release a Travelan® (IMM-124E) IND filed with and approved by FDA Immuron Receives FDA Approval for Travelan IND Application b Market evaluation by Lumanity confirms the Traveler’s Diarrhea AGM Presentation market opportunity for IMM-124E (Travelan®) c